Our top pick for
Building a portfolio
Antares Pharma, Inc is a medical instruments & supplies business based in the US. Antares Pharma shares (ATRS) are listed on the NASDAQ and all prices are listed in US Dollars. Antares Pharma employs 185 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$2.39 - $5.07|
|50-day moving average||$4.10|
|200-day moving average||$3.84|
|Wall St. target price||$6.42|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.33|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Antares Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Antares Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Antares Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Antares Pharma shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Antares Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.2 million.
The EBITDA is a measure of a Antares Pharma's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$149.6 million|
|Operating margin TTM||9.1%|
|Gross profit TTM||$86.5 million|
|Return on assets TTM||4.93%|
|Return on equity TTM||64.74%|
|Market capitalisation||$639.7 million|
TTM: trailing 12 months
There are currently 5.6 million Antares Pharma shares held short by investors – that's known as Antares Pharma's "short interest". This figure is 14.4% up from 4.9 million last month.
There are a few different ways that this level of interest in shorting Antares Pharma shares can be evaluated.
Antares Pharma's "short interest ratio" (SIR) is the quantity of Antares Pharma shares currently shorted divided by the average quantity of Antares Pharma shares traded daily (recently around 881516.5615142). Antares Pharma's SIR currently stands at 6.34. In other words for every 100,000 Antares Pharma shares traded daily on the market, roughly 6340 shares are currently held short.
However Antares Pharma's short interest can also be evaluated against the total number of Antares Pharma shares, or, against the total number of tradable Antares Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Antares Pharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Antares Pharma shares in existence, roughly 30 shares are currently held short) or 0.0338% of the tradable shares (for every 100,000 tradable Antares Pharma shares, roughly 34 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Antares Pharma.
Find out more about how you can short Antares Pharma stock.
We're not expecting Antares Pharma to pay a dividend over the next 12 months.
Antares Pharma's shares were split on a 1:5 basis on 28 January 1999. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Antares Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Antares Pharma shares which in turn could have impacted Antares Pharma's share price.
Over the last 12 months, Antares Pharma's shares have ranged in value from as little as $2.39 up to $5.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Antares Pharma's is 1.4843. This would suggest that Antares Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Antares Pharma, Inc. , a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.